Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study


Por: Torres, T, Sood, S, Yilmaz, O, Vender, RB, Prajapati, V, Puig, L, Megna, M, Marzano, AV, Gisondi, P, Carrascosa, JM, Dauden, E, Llamas-Velasco, M, Balato, A, Leal, BG, Prignano, F, Bellinato, F, Silvi, G, Di Brizzi, E, Potestio, L, Sechi, A, Carrera, CG, López-Ferrer, A, Del-Alcazar, E, Mufti, A, Maul, LV, Piaserico, S, Maul, JT and Yeung, J

Publicada: 1 dic 2025 Ahead of Print: 1 sep 2025
Resumen:
Tildrakizumab is a monoclonal antibody targeting interleukin-23 that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions. While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited. We report real-world drug survival of tildrakizumab in the routine clinical setting.

Filiaciones:
Torres, T:
 Santo Antonio Cent Hosp, Dept Dermatol, Porto, Portugal

 Univ Porto, Inst Biomed Sci Abel Salazar, Porto, Portugal

Leal, BG:
 Univ Porto, Inst Biomed Sci Abel Salazar, Porto, Portugal
ISSN: 03076938





Clinical and Experimental Dermatology
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Letter
Volumen: 50 Número: 12
Páginas: 2496-2497
WOS Id: 001575834800001
ID de PubMed: 40726424

MÉTRICAS